We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blocking Glucose Metabolism Prevents Development of Metabolic Syndrome

By LabMedica International staff writers
Posted on 03 Sep 2018
A novel approach to preventing diabetes and other manifestations of metabolic syndrome, which includes obesity, diabetes, and fatty liver disease, showed promising results in mouse model systems.

The response by the liver to fasting has been proposed as a therapeutic pathway to enhance hepatic and whole-host metabolism. More...
However, the mechanisms underlying these metabolic effects remain unclear.

To help explain these mechanisms, investigators at Washington University School of Medicine (St. Louis, MO, USA) worked with various mouse models to evaluate the role of the enzyme epidermal-type lipoxygenase, eLOX3 (encoded by its gene, Aloxe3), as a potentially novel promotor of the therapeutic fasting response.

The investigators reported in the August 23, 2018, online edition of the journal JCI Insight that Aloxe3 was activated during fasting, glucose withdrawal, or trehalose/trehalose analogue treatment. Aloxe3 in the liver - whether activated by fasting or trehalose - improved the animals' insulin sensitivity as well as increasing calorie burning, raising body temperature, reducing weight gain and fat accumulation, and reducing levels of circulating fats and cholesterol in the blood.

In addition, administration of trehalose in the drinking water of mice fed an obesity-inducing diet protected the animals from developing metabolic disease. Although use of trehalose as a drug in humans is unlikely due to the ease in which it is broken down in the body, trehalose analogues such as lactotrehalose were found to demonstrate similar beneficial effects by activating Aloxe3 while not being as readily denatured.

"We learned that this gene, Aloxe3, improves insulin sensitivity in the same way that common diabetes drugs -- called thiazolidinediones -- improve insulin sensitivity," said senior author Dr. Brian DeBosch, assistant professor of pediatrics at Washington University School of Medicine. "And we showed that Aloxe3 activation in the liver is triggered by both trehalose and by fasting, possibly for the same reason: depriving the liver of glucose. In mice, this gene is turned on as part of what seems to be the normal fasting response. Our data suggest that fasting -- or giving trehalose with a normal diet -- triggers the liver to change the way it processes nutrients, in a beneficial way. And if glucose can be blocked from the liver with a drug, it may be possible to reap the benefits of fasting without strictly limiting food."

Related Links:
Washington University School of Medicine


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.